Monoclonal Antibody for Multiple Myeloma Market - Global Outlook and Forecast 2023-2028

Report ID: 1369937 | Published Date: Jan 2025 | No. of Page: 68 | Base Year: 2024 | Rating: 5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 Monoclonal Antibody for Multiple Myeloma Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Monoclonal Antibody for Multiple Myeloma Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Monoclonal Antibody for Multiple Myeloma Overall Market Size
    2.1 Global Monoclonal Antibody for Multiple Myeloma Market Size: 2021 VS 2028
    2.2 Global Monoclonal Antibody for Multiple Myeloma Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Monoclonal Antibody for Multiple Myeloma Players in Global Market
    3.2 Top Global Monoclonal Antibody for Multiple Myeloma Companies Ranked by Revenue
    3.3 Global Monoclonal Antibody for Multiple Myeloma Revenue by Companies
    3.4 Top 3 and Top 5 Monoclonal Antibody for Multiple Myeloma Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Monoclonal Antibody for Multiple Myeloma Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Monoclonal Antibody for Multiple Myeloma Players in Global Market
        3.6.1 List of Global Tier 1 Monoclonal Antibody for Multiple Myeloma Companies
        3.6.2 List of Global Tier 2 and Tier 3 Monoclonal Antibody for Multiple Myeloma Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Monoclonal Antibody for Multiple Myeloma Market Size Markets, 2021 & 2028
        4.1.2 Elotuzumab
        4.1.3 Daratumumab
        4.1.4 Siltuximab
        4.1.5 Dacetuzumab
        4.1.6 Rituximab
        4.1.7 Other
    4.2 By Type - Global Monoclonal Antibody for Multiple Myeloma Revenue & Forecasts
        4.2.1 By Type - Global Monoclonal Antibody for Multiple Myeloma Revenue, 2017-2022
        4.2.2 By Type - Global Monoclonal Antibody for Multiple Myeloma Revenue, 2023-2028
        4.2.3 By Type - Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Monoclonal Antibody for Multiple Myeloma Market Size, 2021 & 2028
        5.1.2 Hospital
        5.1.3 Drug Center
        5.1.4 Clinic
        5.1.5 Other
    5.2 By Application - Global Monoclonal Antibody for Multiple Myeloma Revenue & Forecasts
        5.2.1 By Application - Global Monoclonal Antibody for Multiple Myeloma Revenue, 2017-2022
        5.2.2 By Application - Global Monoclonal Antibody for Multiple Myeloma Revenue, 2023-2028
        5.2.3 By Application - Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Monoclonal Antibody for Multiple Myeloma Market Size, 2021 & 2028
    6.2 By Region - Global Monoclonal Antibody for Multiple Myeloma Revenue & Forecasts
        6.2.1 By Region - Global Monoclonal Antibody for Multiple Myeloma Revenue, 2017-2022
        6.2.2 By Region - Global Monoclonal Antibody for Multiple Myeloma Revenue, 2023-2028
        6.2.3 By Region - Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Monoclonal Antibody for Multiple Myeloma Revenue, 2017-2028
        6.3.2 US Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.3.3 Canada Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.3.4 Mexico Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Monoclonal Antibody for Multiple Myeloma Revenue, 2017-2028
        6.4.2 Germany Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.4.3 France Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.4.4 U.K. Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.4.5 Italy Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.4.6 Russia Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.4.7 Nordic Countries Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.4.8 Benelux Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Monoclonal Antibody for Multiple Myeloma Revenue, 2017-2028
        6.5.2 China Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.5.3 Japan Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.5.4 South Korea Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.5.5 Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.5.6 India Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Monoclonal Antibody for Multiple Myeloma Revenue, 2017-2028
        6.6.2 Brazil Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.6.3 Argentina Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue, 2017-2028
        6.7.2 Turkey Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.7.3 Israel Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.7.4 Saudi Arabia Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
        6.7.5 UAE Monoclonal Antibody for Multiple Myeloma Market Size, 2017-2028
7 Players Profiles
    7.1 Bristol Myers Squibb
        7.1.1 Bristol Myers Squibb Corporate Summary
        7.1.2 Bristol Myers Squibb Business Overview
        7.1.3 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Major Product Offerings
        7.1.4 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Revenue in Global Market (2017-2022)
        7.1.5 Bristol Myers Squibb Key News
    7.2 Abbvie
        7.2.1 Abbvie Corporate Summary
        7.2.2 Abbvie Business Overview
        7.2.3 Abbvie Monoclonal Antibody for Multiple Myeloma Major Product Offerings
        7.2.4 Abbvie Monoclonal Antibody for Multiple Myeloma Revenue in Global Market (2017-2022)
        7.2.5 Abbvie Key News
    7.3 Janssen Biotech
        7.3.1 Janssen Biotech Corporate Summary
        7.3.2 Janssen Biotech Business Overview
        7.3.3 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Major Product Offerings
        7.3.4 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Revenue in Global Market (2017-2022)
        7.3.5 Janssen Biotech Key News
    7.4 Karyopharm Therapeutics
        7.4.1 Karyopharm Therapeutics Corporate Summary
        7.4.2 Karyopharm Therapeutics Business Overview
        7.4.3 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Major Product Offerings
        7.4.4 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Revenue in Global Market (2017-2022)
        7.4.5 Karyopharm Therapeutics Key News
    7.5 PDL BioPharma
        7.5.1 PDL BioPharma Corporate Summary
        7.5.2 PDL BioPharma Business Overview
        7.5.3 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Major Product Offerings
        7.5.4 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Revenue in Global Market (2017-2022)
        7.5.5 PDL BioPharma Key News
    7.6 Roche
        7.6.1 Roche Corporate Summary
        7.6.2 Roche Business Overview
        7.6.3 Roche Monoclonal Antibody for Multiple Myeloma Major Product Offerings
        7.6.4 Roche Monoclonal Antibody for Multiple Myeloma Revenue in Global Market (2017-2022)
        7.6.5 Roche Key News
    7.7 Seattle Genetics
        7.7.1 Seattle Genetics Corporate Summary
        7.7.2 Seattle Genetics Business Overview
        7.7.3 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Major Product Offerings
        7.7.4 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Revenue in Global Market (2017-2022)
        7.7.5 Seattle Genetics Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. Monoclonal Antibody for Multiple Myeloma Market Opportunities & Trends in Global Market
    Table 2. Monoclonal Antibody for Multiple Myeloma Market Drivers in Global Market
    Table 3. Monoclonal Antibody for Multiple Myeloma Market Restraints in Global Market
    Table 4. Key Players of Monoclonal Antibody for Multiple Myeloma in Global Market
    Table 5. Top Monoclonal Antibody for Multiple Myeloma Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Monoclonal Antibody for Multiple Myeloma Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Monoclonal Antibody for Multiple Myeloma Product Type
    Table 9. List of Global Tier 1 Monoclonal Antibody for Multiple Myeloma Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Monoclonal Antibody for Multiple Myeloma Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Monoclonal Antibody for Multiple Myeloma Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Monoclonal Antibody for Multiple Myeloma Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Monoclonal Antibody for Multiple Myeloma Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Monoclonal Antibody for Multiple Myeloma Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Monoclonal Antibody for Multiple Myeloma Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Monoclonal Antibody for Multiple Myeloma Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2023-2028
    Table 30. Bristol Myers Squibb Corporate Summary
    Table 31. Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Product Offerings
    Table 32. Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 33. Abbvie Corporate Summary
    Table 34. Abbvie Monoclonal Antibody for Multiple Myeloma Product Offerings
    Table 35. Abbvie Monoclonal Antibody for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 36. Janssen Biotech Corporate Summary
    Table 37. Janssen Biotech Monoclonal Antibody for Multiple Myeloma Product Offerings
    Table 38. Janssen Biotech Monoclonal Antibody for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 39. Karyopharm Therapeutics Corporate Summary
    Table 40. Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Product Offerings
    Table 41. Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 42. PDL BioPharma Corporate Summary
    Table 43. PDL BioPharma Monoclonal Antibody for Multiple Myeloma Product Offerings
    Table 44. PDL BioPharma Monoclonal Antibody for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 45. Roche Corporate Summary
    Table 46. Roche Monoclonal Antibody for Multiple Myeloma Product Offerings
    Table 47. Roche Monoclonal Antibody for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 48. Seattle Genetics Corporate Summary
    Table 49. Seattle Genetics Monoclonal Antibody for Multiple Myeloma Product Offerings
    Table 50. Seattle Genetics Monoclonal Antibody for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Monoclonal Antibody for Multiple Myeloma Segment by Type in 2021
    Figure 2. Monoclonal Antibody for Multiple Myeloma Segment by Application in 2021
    Figure 3. Global Monoclonal Antibody for Multiple Myeloma Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Monoclonal Antibody for Multiple Myeloma Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Monoclonal Antibody for Multiple Myeloma Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Monoclonal Antibody for Multiple Myeloma Revenue in 2021
    Figure 8. By Type - Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Monoclonal Antibody for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 12. US Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Monoclonal Antibody for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 16. Germany Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 17. France Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Monoclonal Antibody for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 24. China Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 28. India Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Monoclonal Antibody for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 30. Brazil Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 33. Turkey Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Monoclonal Antibody for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 37. Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Abbvie Monoclonal Antibody for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Janssen Biotech Monoclonal Antibody for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. PDL BioPharma Monoclonal Antibody for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Roche Monoclonal Antibody for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Seattle Genetics Monoclonal Antibody for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
68
Frequently Asked Questions
Monoclonal Antibody for Multiple Myeloma Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Monoclonal Antibody for Multiple Myeloma Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Monoclonal Antibody for Multiple Myeloma Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Ixazomib Market

This report contains market size and forecasts of Ixazomib in global, including the following mar ... Read More

Elotuzumab Market

This report contains market size and forecasts of Elotuzumab in global, including the following m ... Read More

Carmustine Market

This report contains market size and forecasts of Carmustine in global, including the following m ... Read More